| Literature DB >> 19440415 |
Nickolas D Zaller1, Alexander R Bazazi, Lavinia Velazquez, Josiah D Rich.
Abstract
Injection drug use (IDU) continues to be a significant public health issue in the U.S. and internationally, and there is evidence to suggest that the burden of injection drug use and associated morbidity and mortality falls disproportionately on minority communities. IDU is responsible for a significant portion of new and existing HIV/AIDS cases in many parts of the world. In the U.S., the prevalence of HIV and hepatitis C virus is higher among populations of African-American and Latino injection drug users (IDUs) than among white IDUs. Methadone maintenance therapy (MMT) has been demonstrated to effectively reduce opiate use, HIV risk behaviors and transmission, general mortality and criminal behavior, but opiate-dependent minorities are less likely to access MMT than whites. A better understanding of the obstacles minority IDUs face accessing treatment is needed to engage racial and ethnic disparities in IDU as well as drug-related morbidity and mortality. In this study, we explore knowledge, attitudes and beliefs about methadone among 53 out-of-treatment Latino and African-American IDUs in Providence, RI. Our findings suggest that negative perceptions of methadone persist among racial and ethnic minority IDUs in Providence, including beliefs that methadone is detrimental to health and that people should attempt to discontinue methadone treatment. Additional potential obstacles to entering methadone therapy include cost and the difficulty of regularly attending a methadone clinic as well as the belief that an individual on MMT is not abstinent from drugs. Substance use researchers and treatment professionals should engage minority communities, particularly Latino communities, in order to better understand the treatment needs of a diverse population, develop culturally appropriate MMT programs, and raise awareness of the benefits of MMT.Entities:
Keywords: HIV/AIDS; Injection drug use; health disparities; methadone
Mesh:
Substances:
Year: 2009 PMID: 19440415 PMCID: PMC2672350 DOI: 10.3390/ijerph6020787
Source DB: PubMed Journal: Int J Environ Res Public Health ISSN: 1660-4601 Impact factor: 3.390
Participant characteristics.
| Total, n (%) | 53 (100%) |
|---|---|
| 20 – 29 y | 6 (12%) |
| 30 – 39 y | 19 (37%) |
| 40 – 49 y | 21 (41%) |
| 50 – 59 y | 5 (10%) |
| Female | 11 (21%) |
| Male | 41 (79%) |
| Black, non-Hispanic | 14 (26%) |
| Hispanic (any race) | 39 (74%) |
| USA | 14 (29%) |
| Puerto Rico | 31 (63%) |
| Other or Multiple | 4 (8%) |
| Heroin | 34 (64%) |
| Cocaine/Crack | 5 (9%) |
| Heroin and Cocaine/Crack | 14 (26%) |
| Yes | 27 (51%) |
| No | 26 (49%) |
| Individuals | 13 (27%) |
| Syringe Exchange | 20 (41%) |
| Pharmacy | 20 (41%) |
| Other | 4 (8%) |
| Yes | 32 (60%) |
| No | 21 (40%) |
All participants indicated heroin use, but survey responses reflect their primary drug of choice.
Percents do not add up to 100 since participants could indicate more than one response.
Attitudes and Beliefs.
| Agree or Don’t Know | 38 (73%) | ||
| Disagree | 14 (27%) | <0.01 | |
| Agree | 41 (77%) | ||
| Disagree or Don’t Know | 12 (23%) | <0.01 | |
| Agree | 20 (38%) | ||
| Disagree or Don’t Know | 33 (62%) | 0.09 | |
| Agree | 35 (66%) | ||
| Disagree or Don’t Know | 18 (34%) | 0.03 | |
| Agree | 37 (70%) | ||
| Disagree or Don’t Know | 16 (30%) | 0.01 | |
| Agree | 38 (72%) | ||
| Disagree or Don’t Know | 15 (28%) | <0.01 | |
| Agree | 37 (70%) | ||
| Disagree or Don’t Know | 16 (30%) | 0.01 | |
| Agree | 33 (62%) | ||
| Disagree or Don’t Know | 20 (38%) | 0.01 | |
| Agree | 18 (37%) | ||
| Disagree or Don’t Know | 31 (63%) | 0.09 | |
| Agree | 42 (86%) | ||
| Disagree or Don’t Know | 7 (14%) | <0.01 | |
| Agree | 28 (58%) | ||
| Disagree or Don’t Know | 20 (42%) | 0.32 | |